| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 02/11/2021 | 14:00 | GlobeNewswire Inc. | ALX Oncology Announces Upcoming Virtual Investor Conference Participation | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 21/10/2021 | 13:00 | GlobeNewswire Inc. | ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 21/10/2021 | 01:11 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 07/10/2021 | 13:00 | GlobeNewswire Inc. | ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 05/10/2021 | 14:30 | Business Wire | Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 01/10/2021 | 14:00 | GlobeNewswire Inc. | ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 16/09/2021 | 13:00 | GlobeNewswire Inc. | ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 14/09/2021 | 13:00 | PR Newswire (US) | Lightstone Ventures Raises $375 Million Fund | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 10/09/2021 | 14:55 | Edgar (US Regulatory) | Schedule 13g | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 27/08/2021 | 23:21 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 13/08/2021 | 22:33 | Edgar (US Regulatory) | Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 12/08/2021 | 22:44 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 12/08/2021 | 22:05 | GlobeNewswire Inc. | ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 28/07/2021 | 13:00 | GlobeNewswire Inc. | ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 03/07/2021 | 13:15 | GlobeNewswire Inc. | ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients wi... | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 15/06/2021 | 18:20 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 14/06/2021 | 13:00 | GlobeNewswire Inc. | ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 10/06/2021 | 13:40 | Dow Jones News | ALX Oncology, Eli Lilly to Evaluate Gastric Cancer Treatment | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 10/06/2021 | 13:00 | GlobeNewswire Inc. | ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patien... | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 19/05/2021 | 23:27 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 17/05/2021 | 22:05 | GlobeNewswire Inc. | ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 10/05/2021 | 13:00 | GlobeNewswire Inc. | ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizum... | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 05/05/2021 | 22:22 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 29/04/2021 | 22:03 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 21/04/2021 | 22:05 | GlobeNewswire Inc. | ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 05/04/2021 | 13:00 | GlobeNewswire Inc. | ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148 | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 18/03/2021 | 21:27 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 18/03/2021 | 21:05 | GlobeNewswire Inc. | ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Hi... | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 15/03/2021 | 12:00 | GlobeNewswire Inc. | ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors | NASDAQ:ALXO | ALX Oncology Holdings Inc |
| 04/03/2021 | 22:05 | GlobeNewswire Inc. | ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics | NASDAQ:ALXO | ALX Oncology Holdings Inc |